- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 249/10 - 1,2,4-TriazolesHydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 249/10
Total number of patents in this class: 209
10-year publication summary
10
|
19
|
15
|
10
|
16
|
9
|
9
|
11
|
8
|
2
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Theravance Biopharma R&D IP, LLC | 458 |
31 |
BASF SE | 20926 |
7 |
Bayer Pharma AG | 1053 |
7 |
Corteva Agriscience LLC | 2669 |
7 |
Theravance, Inc. | 66 |
6 |
Synta Pharmaceuticals Corp. | 179 |
5 |
Taisho Pharmaceutical Co., Ltd. | 869 |
5 |
KalVista Pharmaceuticals Limited | 110 |
4 |
Novartis AG | 10847 |
3 |
F. Hoffmann-La Roche AG | 7930 |
3 |
Vertex Pharmaceuticals Incorporated | 1599 |
3 |
Bionomics Limited | 88 |
3 |
Canopy Growth Corporation | 220 |
3 |
FMC Corporation | 845 |
3 |
SK Biopharmaceuticals Co., Ltd. | 261 |
3 |
Tokyo Ohka Kogyo Co., Ltd. | 1543 |
3 |
Centre National de La Recherche Scientifique | 10421 |
2 |
The General Hospital Corporation | 4726 |
2 |
Ardea Biosciences, Inc. | 72 |
2 |
BeiGene, Ltd. | 367 |
2 |
Other owners | 105 |